| Literature DB >> 30008824 |
Canmei Zhong1, Mingkai Zhuang1, Xiazhong Wang1, Jianying Li1, Zhixin Chen1, Yuehong Huang1, Fenglin Chen1.
Abstract
The role of 12-lipoxygenase (12-LOX) in tumorigenesis has been well established in several types of human cancer, including gastric cancer. It was reported that epithelial-mesenchymal transition (EMT) contributes to tumor invasion and metastasis. However, whether 12-LOX promotes the invasion and metastasis of human gastric cancer cells via EMT remains to be elucidated. In the present study, the expression of 12-LOX and EMT markers, N-cadherin and E-cadherin, was evaluated in gastric cancer and adjacent normal mucosa samples by immunohistochemical analysis. 12-LOX-overexpressing gastric cancer cells were established via lentiviral transfection of SCG-7901 cells. Wound-healing and Transwell assays were performed to examine the regulation of cell metastasis and invasion by 12-LOX. Furthermore, the regulation of N-cadherin expression by 12-LOX was evaluated using reverse transcription-quantitative polymerase chain reaction and western blotting. The results revealed that the expression of 12-LOX and N-cadherin was significantly higher in gastric cancer compared with that in adjacent normal mucosa tissues (P<0.05). By contrast, the expression of E-cadherin was significantly decreased in gastric cancer compared with that in adjacent normal mucosa tissues (P<0.05). Furthermore, the expression of 12-LOX was positively associated with N-cadherin expression in gastric cancer tissues. 12-LOX-overexpressing gastric cancer cells exhibited significantly increased invasion and migration abilities compared with the empty vector and control groups. The expression of N-cadherin in 12-LOX-overexpressing gastric cancer cells was increased compared with that in the empty vector and control groups. The present study suggests that EMT may be involved in the promotion of the invasion and metastasis of human gastric cancer cells by 12-LOX.Entities:
Keywords: 12-lipoxygenase; epithelial-mesenchymal transition; gastric carcinoma; invasion; metastasis
Year: 2018 PMID: 30008824 PMCID: PMC6036329 DOI: 10.3892/ol.2018.8808
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Primer sequences for 12-LOX, N-cadherin and GAPDH.
| Gene | Primer (5′-3′) |
|---|---|
| 12-LOX | Forward: ATGGCCCTCAAACGTGTTTAC |
| Reverse: GCACTGGCGAACCTTCTCA | |
| N-cadherin | Forward: GCGTCTGTAGAGGCTTCTGG |
| Reverse: AAATCTGCAGGCTCACTGCT | |
| GAPDH | Forward: CATCAGCAATGCCTCCTGCAC |
| Reverse: TGAGTCCTTCCACGATACCAA | |
| AGTT |
12-LOX, 12-lipoxygenase.
Figure 1.Representative expression levels of 12-LOX, E-cadherin and N-cadherin in GC and adjacent normal gastric mucosa tissues, as analyzed by immunohistochemistry (magnification, ×400). The protein expression level of 12-LOX and N-cadherin was increased, and that of E-cadherin was decreased, in GC tissue compared with adjacent normal gastric mucosa tissue. 12-LOX, 12-lipoxygenase; GC, gastric cancer.
Expression of 12-LOX, N-cadherin and E-cadherin in 105 cases of gastric cancer and 43 gastric normal mucosa tissues.
| Protein expression | Gastric cancer tissue | Gastric normal mucosa tissue | P-value |
|---|---|---|---|
| 12-LOX | |||
| Positive | 65 | 14 | 0.001 |
| Negative | 40 | 29 | |
| N-cadherin | |||
| Positive | 63 | 11 | <0.001 |
| Negative | 42 | 32 | |
| E-cadherin | |||
| Positive | 41 | 24 | 0.046 |
| Negative | 64 | 19 |
χ2 test. 12-LOX, 12-lipoxygenase.
Association between 12-LOX, E-cadherin and N-cadherin protein expression level and clinicopathological features in 105 cases of gastric cancer (some patient data is missing).
| 12-LOX expression | E-cadherin expression | N-cadherin expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Low, n | High, n | P-value | Low, n | High, n | P-value | Low, n | High, n | P-value |
| Age, years | |||||||||
| ≤60 | 18 | 29 | 0.751 | 34 | 13 | 0.031[ | 21 | 26 | 0.291 |
| >60 | 24 | 34 | 30 | 28 | 20 | 38 | |||
| Sex | |||||||||
| Male | 35 | 45 | 0.164 | 46 | 34 | 0.198 | 31 | 49 | 0.912 |
| Female | 7 | 18 | 18 | 7 | 10 | 15 | |||
| Tumor size, cm | |||||||||
| <5 | 24 | 29 | 0.296 | 32 | 21 | 0.902 | 27 | 26 | 0.011[ |
| ≥5 | 18 | 34 | 32 | 20 | 14 | 38 | |||
| Tumor invasion | |||||||||
| T1-T2 | 11 | 17 | 0.986 | 18 | 10 | 0.645 | 14 | 14 | 0.145 |
| T3-T4 | 30 | 46 | 45 | 31 | 26 | 50 | |||
| Differentiation | |||||||||
| Poor | 32 | 20 | 0.670 | 14 | 38 | 0.021[ | 29 | 23 | 0.121 |
| Middle-well | 24 | 18 | 21 | 21 | 30 | 12 | |||
| Clinical stage | |||||||||
| I+II | 17 | 27 | 0.811 | 29 | 15 | 0.381 | 19 | 25 | 0.466 |
| III+IV | 25 | 36 | 35 | 26 | 22 | 39 | |||
| Lymph node metastasis | |||||||||
| Negative | 9 | 17 | 0.562 | 16 | 10 | 0.908 | 11 | 15 | 0.645 |
| Positive | 32 | 46 | 47 | 31 | 29 | 49 | |||
χ2 test. 12-LOX, 12-lipoxygenase.
P<0.05.
Association between the expression levels of 12-LOX and N-cadherin protein expression in 105 gastric cancer tissues.
| 12-LOX expression | ||||
|---|---|---|---|---|
| N-cadherin expression | Low | High | R | P-value |
| Low | 23 | 18 | 0.263 | 0.007 |
| High | 19 | 45 | ||
χ2 test. 12-LOX, 12-lipoxygenase.
Figure 2.SGC-7901 GC cells were transfected with the 12-LOX overexpression vector or empty vector. (A) Successfully transfected cells fluoresced green. The mRNA expression of 12-LOX was significantly increased in the LV-12-LOX group compared with that in the LV-vector and control groups (*P<0.05), which was reflected at the protein level. (B) The wound-healing assay demonstrated the migration of the 3 groups at 0 and 24 h. The migratory ability of LV-12-LOX GC cells was significantly increased compared with the LV-vector and control group cells (*P<0.05). (C) Migration and invasion assays revealed that the number of cancer cells that migrated or invaded through the Transwell insert was significantly increased in the LV-12-LOX group compared with that in the LV-vector and control groups (*P<0.05). 12-LOX, 12-lipoxygenase; LV, lentivirus; GC, gastric cancer.
Figure 3.12-LOX promotes N-cadherin expression in gastric cancer cells. (A) The mRNA expression level of N-cadherin was determined by reverse transcription-quantitative polymerase chain reaction (*P<0.05). (B) The protein expression level of N-cadherin was determined by western blotting. 12-LOX, 12-lipoxygenase; LV, lentivirus.